# Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

> **NCT03525600** · PHASE3 · COMPLETED · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 621 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** APL-2
- **DRUG:** APL-2
- **OTHER:** Sham Procedure
- **OTHER:** Sham Procedure

## Key facts

- **NCT ID:** NCT03525600
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-31
- **Primary completion:** 2021-06-21
- **Final completion:** 2022-06-20
- **Target enrollment:** 621 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03525600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03525600, "Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03525600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*